|
Teva Files Another Petition to Delay Generic Copaxone
In its latest effort to throw down barriers to any company that attempts to bring to market a generic form of its multiple sclerosis (MS) drug, Copaxone, Teva Pharmaceutical Industries has filed a third citizen’s petition with the FDA, this time asking the agency to convene a multidisciplinary advisory panel to consider the approval of any follow-on glatiramer acetate products.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives